Now showing items 1142-1161 of 2900

    • Health-related quality of life results from the phase III CheckMate 067 study. 

      Schadendorf, D; Larkin, J; Wolchok, J; Hodi, FS; Chiarion-Sileni, V; Gonzalez, R; Rutkowski, P; Grob, J-J; Cowey, CL; Lao, C; Wagstaff, J; Callahan, MK; Postow, MA; Smylie, M; Ferrucci, PF; Dummer, R; Hill, A; Taylor, F; Sabater, J; Walker, D; Kotapati, S; Abernethy, A; Long, GV (2017-09)
      BACKGROUND: Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as ...
    • Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. 

      Brahmer, JR; Rodríguez-Abreu, D; Robinson, AG; Hui, R; Csőszi, T; Fülöp, A; Gottfried, M; Peled, N; Tafreshi, A; Cuffe, S; O'Brien, M; Rao, S; Hotta, K; Zhang, J; Lubiniecki, GM; Deitz, AC; Rangwala, R; Reck, M (2017-12)
      BACKGROUND: In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer ...
    • Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. 

      Zhang, B; Shu, X-O; Delahanty, RJ; Zeng, C; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Wen, W; Long, J; Li, C; Dunning, AM; Chang-Claude, J; Shah, M; Perkins, BJ; Czene, K; Darabi, H; Eriksson, M; Bojesen, SE; Nordestgaard, BG; Nielsen, SF; Flyger, H; Lambrechts, D; Neven, P; Wildiers, H; Floris, G; Schmidt, MK; Rookus, MA; van den Hurk, K; de Kort, WLAM; Couch, FJ; Olson, JE; Hallberg, E; Vachon, C; Rudolph, A; Seibold, P; Flesch-Janys, D; Peto, J; Dos-Santos-Silva, I; Fletcher, O; Johnson, N; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Li, J; Humphreys, K; Brand, J; Guénel, P; Truong, T; Cordina-Duverger, E; Menegaux, F; Burwinkel, B; Marme, F; Yang, R; Surowy, H; Benitez, J; Zamora, MP; Perez, JIA; Cox, A; Cross, SS; Reed, MWR; Andrulis, IL; Knight, JA; Glendon, G; Tchatchou, S; Sawyer, EJ; Tomlinson, I; Kerin, MJ; Miller, N; Chenevix-Trench, G; kConFab Investigators, Australian Ovarian Study Group; Haiman, CA; Henderson, BE; Schumacher, F; Marchand, LL; Lindblom, A; Margolin, S; Hooning, MJ; Martens, JWM; Tilanus-Linthorst, MMA; Collée, JM; Hopper, JL; Southey, MC; Tsimiklis, H; Apicella, C; Slager, S; Toland, AE; Ambrosone, CB; Yannoukakos, D; Giles, GG; Milne, RL; McLean, C; Fasching, PA; Haeberle, L; Ekici, AB; Beckmann, MW; Brenner, H; Dieffenbach, AK; Arndt, V; Stegmaier, C; Swerdlow, AJ; Ashworth, A; Orr, N; Jones, M; Figueroa, J; Garcia-Closas, M; Brinton, L; Lissowska, J; Dumont, M; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Brauch, H; Brüning, T; Ko, Y-D; Peterlongo, P; Manoukian, S; Bonanni, B; Radice, P; Bogdanova, N; Antonenkova, N; Dörk, T; Mannermaa, A; Kataja, V; Kosma, V-M; Hartikainen, JM; Devilee, P; Seynaeve, C; Van Asperen, CJ; Jakubowska, A; Lubiński, J; Jaworska-Bieniek, K; Durda, K; Hamann, U; Torres, D; Schmutzler, RK; Neuhausen, SL; Anton-Culver, H; Kristensen, VN; Grenaker Alnæs, GI; DRIVE Project; Pierce, BL; Kraft, P; Peters, U; Lindstrom, S; Seminara, D; Burgess, S; Ahsan, H; Whittemore, AS; John, EM; Gammon, MD; Malone, KE; Tessier, DC; Vincent, D; Bacot, F; Luccarini, C; Baynes, C; Ahmed, S; Maranian, M; Healey, CS; González-Neira, A; Pita, G; Alonso, MR; Álvarez, N; Herrero, D; Pharoah, PDP; Simard, J; Hall, P; Hunter, DJ; Easton, DF; Zheng, W (2015-11)
      BACKGROUND: Epidemiological studies have linked adult height with breast cancer risk in women. However, the magnitude of the association, particularly by subtypes of breast cancer, has not been established. Furthermore, ...
    • Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. 

      Lophatananon, A; Stewart-Brown, S; Kote-Jarai, Z; Olama, AAA; Garcia, SB; Neal, DE; Hamdy, FC; Donovan, JL; Giles, GG; Fitzgerald, LM; Southey, MC; Pharoah, P; Pashayan, N; Gronberg, H; Wiklund, F; Aly, M; Stanford, JL; Brenner, H; Dieffenbach, AK; Arndt, V; Park, JY; Lin, H-Y; Sellers, T; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Spurdle, A; Clements, JA; APCB BioResource; PRACTICAL consortium; Easton, D; Eeles, RA; Muir, K (2017-08-22)
      BACKGROUND: Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer. METHODS: We analysed ...
    • Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. 

      Vogelzang, NJ; Coleman, RE; Michalski, JM; Nilsson, S; O'Sullivan, JM; Parker, C; Widmark, A; Thuresson, M; Xu, L; Germino, J; Sartor, O (2016-08-08)
      Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding risk ...
    • Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. 

      Vogelzang, NJ; Coleman, RE; Michalski, JM; Nilsson, S; O'Sullivan, JM; Parker, C; Widmark, A; Thuresson, M; Xu, L; Germino, J; Sartor, O (2016-08-08)
      Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding risk ...
    • Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods 

      Schild, LJ; Phillips, DH; Osborne, MR; Hewer, A; Beland, FA; Churchwell, MI; Brown, K; Gaskell, M; Wright, E; Poirier, MC (OXFORD UNIV PRESS, 2005-03)
      Liver homogenates from rats fed tamoxifen (TAM) in the diet were shared among four different laboratories. TAM-DNA adducts were assayed by high pressure liquid chromatography-electrospray tandem mass spectrometry ...
    • HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 

      Bartlett, JMS; Ahmed, I; Regan, MM; Sestak, I; Mallon, EA; Dell'Orto, P; Thurlimann, B; Seynaeve, C; Putter, H; Van de Velde, CJH; Brookes, CL; Forbes, JF; Viale, G; Cuzick, J; Dowsett, M; Rea, DW; Inhibitor, TA (2017-07)
    • HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. 

      Bartlett, JMS; Ahmed, I; Regan, MM; Sestak, I; Mallon, EA; Dell'Orto, P; Thürlimann, B; Seynaeve, C; Putter, H; Van de Velde, CJH; Brookes, CL; Forbes, JF; Viale, G; Cuzick, J; Dowsett, M; Rea, DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG) (2017-07)
      BACKGROUND: A meta-analysis of the effects of HER2 status, specifically within the first 2-3 years of adjuvant endocrine therapy, has the potential to inform patient selection for upfront aromatase inhibitor (AI) therapy ...
    • HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. 

      Martins, CD; Da Pieve, C; Burley, TA; Smith, R; Ciobota, DM; Allott, L; Harrington, KJ; Oyen, WJG; Smith, G; Kramer-Marek, G (2018-04-15)
      Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). ...
    • The Heterocellular Emergence of Colorectal Cancer. 

      Tape, CJ (2017-02)
      Tissues contain multiple different cell types and can be considered to be heterocellular systems. Signaling between different cells allows tissues to achieve phenotypes that no cell type can achieve in isolation. Such ...
    • Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. 

      López-Knowles, E; Gao, Q; Cheang, MC; Morden, J; Parker, J; Martin, LA; Pinhel, I; McNeill, F; Hills, M; Detre, S; Afentakis, M; Zabaglo, L; Dodson, A; Skene, A; Holcombe, C; Robertson, J; Smith, I; Bliss, JM; Dowsett, M (2016-01)
      Gene expression is widely used for the characterisation of breast cancers. Variability due to tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect measurements but is ...
    • Heterogeneous proliferative potential in regenerative adult newt cardiomyocytes. 

      Bettencourt-Dias, M; Mittnacht, S; Brockes, JP (2003-10)
      Adult newt cardiomyocytes, in contrast to their mammalian counterparts, can proliferate after injury and contribute to the functional regeneration of the heart. In order to understand the mechanisms underlying this plasticity ...
    • Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. 

      Crusz, SM; Tang, YZ; Sarker, S-J; Prevoo, W; Kiyani, I; Beltran, L; Peters, J; Sahdev, A; Bex, A; Powles, T; Gerlinger, M (2016-11-14)
      BACKGROUND: Molecular intratumour heterogeneity (ITH) is common in clear cell renal carcinomas (ccRCCs). However, it remains unknown whether this is mirrored by heterogeneity of drug responses between metastases in the ...
    • High altitude adaptation in Daghestani populations from the Caucasus 

      Kozarewa, Iwanka (2012-03)
      We have surveyed 15 high-altitude adaptation candidate genes for signals of positive selection in North Caucasian highlanders using targeted re-sequencing. A total of 49 unrelated Daghestani from three ethnic groups (Avars, ...
    • High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. 

      Perez-Lopez, R; Roda, D; Jimenez, B; Brown, J; Mateo, J; Carreira, S; Lopez, J; Banerji, U; Molife, LR; Koh, D-M; Kaye, SB; de Bono, JS; Tunariu, N; Yap, TA (2017-11-28)
      Despite impressive clinical activity in patients with germline BRCA1 and BRCA2 (BRCA1/2) mutant cancers, antitumor responses to poly(ADP-Ribose) polymerase (PARP) inhibitors are variable. We set out to assess the rate of ...
    • High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia 

      Milligan, DW; Kochethu, G; Dearden, C; Matutes, E; MacConkey, C; Catovsky, D; Grp, NCRIHS (BLACKWELL PUBLISHING, 2006-04)
      We report a high incidence of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) in patients entered into the Medical Research Council Chronic Lymphocytic Leukaemia-5 trial. Of 115 newly diagnosed patients treated ...
    • High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance 

      Cocker, HA; Hobbs, SM; Tiffin, N; Pritchard-Jones, K; Pinkerton, CR; Kelland, LR (2001-11-30)
      The MDM2 protein is known to be overexpressed in some sarcomas including rhabdomyosarcoma. However, the extent to which the MDM2 protein influences sensitivity to chemotherapeutic drugs is unclear. We have analysed this ...
    • High Precision Focused Irradiation in the Form of Fractionated Stereotactic Conformal Radiotherapy (SCRT) for Benign Meningiomas Predominantly in the Skull Base Location 

      Jalali, R; Loughrey, C; Baumert, B; Perks, J; Warrington, AP; Traish, D; Ashley, S; Brada, M (2002)
      ABSTRACT: OBJECTIVE: To present early clinical results of stereotactic conformal radiotherapy (SCRT) in patients with benign predominantly skull base meningiomas. MATERIAL AND METHODS: Between August 1994 and August 1999, ...
    • High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H 

      Dearden, CE; Matutes, E; Cazin, B; Tjonnfjord, GE; Parreira, A; Nomdedeu, B; Leoni, P; Clark, FJ; Radia, D; Rassam, SMB; Roques, T; Ketterer, N; Brito-Babapulle, V; Dyer, MJS; Catovsky, D (AMER SOC HEMATOLOGY, 2001-09-15)
      T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-resistant malignancy with a median survival of 7.5 months. Preliminary results indicated a high remission induction rate with the human CD52 antibody, CAMPATH-1H. ...